Our ACCEL technology platform represents an exciting new approach to the precise control and targeting of CAR-T cell to manage and cure cancer. Xyphos is currently evaluating partnership opportunities for research and development programs to exploit applications of our best-in-class convertible technologies.
To partner with us please contact:
Chuck Vacin, MBA
Director, Business Development
Office: (650) 243-2951